期刊
JOURNAL OF CANCER
卷 12, 期 9, 页码 2735-2746出版社
IVYSPRING INT PUBL
DOI: 10.7150/jca.57334
关键词
immune checkpoint; PD-1; PD-L1; PD-L2; T cell; cancer immunotherapy
类别
资金
- American Cancer Society [RSG-17-064-01-TBE]
Immune checkpoint blockade is a promising strategy for treating cancer by reactivating anti-tumor immunity, but the response rates and resistance towards current anti-PD-1/PD-L1 therapies remain challenges. New perspectives are needed to overcome these hurdles for successful cancer treatment.
Cancer cells can evade the attack from host immune systems via hijacking the regulatory circuits mediated by immune checkpoints. Therefore, reactivating the antitumor immunity by blockade of immune checkpoints is considered as a promising strategy to treat cancer. Programmed death protein 1 (PD-1) and its ligand programmed death-ligand 1 (PD-L1) are critical immune checkpoint proteins that responsible for negative regulation of the stability and the integrity of T-cell immune function. Anti-PD-1/PD-L1 drugs have been developed for immune checkpoint blockade and can induce clinical responses across different types of cancers, which provides a new hope to cure cancer. However, the patients' response rates to current anti-PD-1 or anti-PD-L1 therapies are still low and many initial responders finally develop resistance to these therapies. In this review, we provides a snapshot of the PD-1/PD-L1 molecular structure, mechanisms controlling their expression, signaling modulated by PD-1/PD-L1, current anti-PD-1/PD-L1 therapies, and the future perspectives to overcome the resistance.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据